The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis

Autoimmunity Reviews

Volumn 19, Issue 1, 2020, Pages

  Favalli, Ennio Giulio ^a   Matucci Cerinic, Marco ^b   Szekanecz, Zoltan ^c  

^a Department of Rheumatology   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Biologic agents; Efficacy; JAK inhibitors; Personalised medicine; Rheumatoid arthritis; Safety profile

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 1; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE INHIBITOR; METHOTREXATE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR;

ABNORMAL LABORATORY RESULT; B LYMPHOCYTE; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HERPES ZOSTER; HUMAN; IMMUNOCOMPETENT CELL; INFECTION; INFLAMMATORY DISEASE; LACTATION; LYMPHOCYTE DEPLETION; PATIENT COMPLIANCE; PATIENT-REPORTED OUTCOME; PERSONALIZED MEDICINE; PREGNANCY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THROMBOEMBOLISM; CHEMISTRY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; BIOLOGICAL PRODUCTS; HUMANS;

EID: 85075342214     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2019.102421     Document Type: Review

References (129)

1. Myasoedova, E, Crowson, CS, Kremers, HM, Therneau, TM, Gabriel, SE, Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum 62:6 (2010), 1576–1582.
2. Silman, AJ, Pearson, JE, Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 4:Suppl. 3 (2002), S265–S272.
3. McInnes, IB, Schett, G, The pathogenesis of rheumatoid arthritis. N Engl J Med 365:23 (2011), 2205–2219.
4. Lefevre, S, Knedla, A, Tennie, C, Kampmann, A, Wunrau, C, Dinser, R, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 15:12 (2009), 1414–1420.
5. Avina-Zubieta, JA, Choi, HK, Sadatsafavi, M, Etminan, M, Esdaile, JM, Lacaille, D, Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59:12 (2008), 1690–1697.
6. Firestein, GS, The disease formerly known as rheumatoid arthritis. Arthritis Res Ther, 16(3), 2014, 114.
7. Holmqvist, M, Ljung, L, Askling, J, Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact?. Ann Rheum Dis 77:1 (2018), 85–91.
8. Favalli, EG, Biggioggero, M, Meroni, PL, Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug?. Autoimmun Rev 13:11 (2014), 1102–1108.
9. Smolen, JS, Aletaha, D, Barton, A, Burmester, GR, Emery, P, Firestein, GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers, 4, 2018, 18001.
10. McInnes, IB, Buckley, CD, Isaacs, JD, Cytokines in rheumatoid arthritis - shaping the immunological landscape. Nat Rev Rheumatol 12:1 (2016), 63–68.
11. Chighizola, CB, Favalli, EG, Meroni, PL, Novel mechanisms of action of the biologicals in rheumatic diseases. Clin Rev Allergy Immunol 47:1 (2014), 6–16.
12. Smolen, JS, Landewé, R, Bijlsma, J, Burmester, G, Chatzidionysiou, K, Dougados, M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:6 (2017), 960–977.
13. Biggioggero, M, Favalli, EG, Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. Drug Dev Res 75:Suppl. 1 (2014), S38–S41.
14. Sarzi-Puttini, P, Antivalle, M, Marchesoni, A, Favalli, EG, Gorla, R, Filippini, M, et al. Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo 60:4 (2008), 290–295.
15. Marchesoni, A, Zaccara, E, Gorla, R, Bazzani, C, Sarzi-Puttini, P, Atzeni, F, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173 (2009), 837–846.
16. Iannone, F, Sinigaglia, L, Favalli, EG, Sarzi-Puttini, P, Atzeni, F, Caporali, R, et al. Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. Clin Rheumatol 35:11 (2016), 2649–2656.
17. Iannone, F, Ferraccioli, G, Sinigaglia, L, Favalli, EG, Sarzi-Puttini, P, Atzeni, F, et al. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEA. Clin Rheumatol 37:2 (2018), 315–321.
18. Caporali, R, Sarzi-Puttini, P, Atzeni, F, Gorla, R, Filippini, M, Marchesoni, A, et al. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev 9:6 (2010), 465–469.
19. de Hair, MJH, Jacobs, JWG, Schoneveld, JLM, van Laar, JM, Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford), 2017, 10.1093/rheumatology/kex349 [Epub ahead of print].
20. Favalli, EG, Bugatti, S, Biggioggero, M, Caporali, R, Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. Biomed Res Int, 2014, 2014, 831603.
21. Cantini, F, Niccoli, L, Nannini, C, Cassarà, E, Kaloudi, O, Giulio Favalli, E, et al. (ITABIO) IbftTBt. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum 45:5 (2016), 519–532.
22. Sebastiani, M, Anelli, MG, Atzeni, F, Bazzani, C, Farina, I, Fedele, AL, et al. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register. Joint Bone Spine 81:6 (2014), 508–512.
23. Cantini, F, Niccoli, L, Nannini, C, Cassarà, E, Kaloudi, O, Giulio Favalli, E, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum 47:2 (2017), 183–192.
24. Favalli, EG, Biggioggero, M, Marchesoni, A, Meroni, PL, Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford) 53:9 (2014), 1664–1668.
25. Todoerti, M, Favalli, EG, Iannone, F, Olivieri, I, Benucci, M, Cauli, A, et al. Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology (Oxford) 57:Suppl. 7 (2018), vii42–vii53.
26. Favalli, EG, Raimondo, MG, Becciolini, A, Crotti, C, Biggioggero, M, Caporali, R, The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. Autoimmun Rev 16:12 (2017), 1185–1195.
27. Ferguson, FM, Gray, NS, Kinase inhibitors: the road ahead. Nat Rev Drug Discov 17:5 (2018), 353–377.
28. Schwartz, DM, Bonelli, M, Gadina, M, O'Shea, JJ, Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12:1 (2016), 25–36.
29. Taylor, PC, Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 58:Supplement_1 (2019), i17–i26.
30. Clark, JD, Flanagan, ME, Telliez, JB, Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 57:12 (2014), 5023–5038.
31. Genovese, MC, Kremer, J, Zamani, O, Ludivico, C, Krogulec, M, Xie, L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374:13 (2016), 1243–1252.
32. Yamaoka, K., Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol 32 (2016), 29–33.
33. Moroncini, G, Calogera, G, Benfaremo, D, Gabrielli, A, Biologics in inflammatory immune-mediated systemic diseases. Curr Pharm Biotechnol 18:12 (2017), 1008–1016.
34. Szekanecz, Z, Szanto, S, Szabo, Z, Vancsa, A, Szamosi, S, Bodnar, N, et al. Biologics - beyond the joints. Autoimmun Rev 9:12 (2010), 820–824.
35. Schwartz, DM, Kanno, Y, Villarino, A, Ward, M, Gadina, M, O'Shea, JJ, JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 16:12 (2017), 843–862.
36. Davis, MI, Hunt, JP, Herrgard, S, Ciceri, P, Wodicka, LM, Pallares, G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29:11 (2011), 1046–1051.
37. Weinblatt, ME, Genovese, MC, Ho, M, Hollis, S, Rosiak-Jedrychowicz, K, Kavanaugh, A, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol 66:12 (2014), 3255–3264.
38. Mocsai, A, Kovacs, L, Gergely, P, What is the future of targeted therapy in rheumatology: biologics or small molecules?. BMC Med, 12, 2014, 43.
39. Guyot, P, Taylor, PC, Christensen, R, Pericleous, L, Drost, P, Eijgelshoven, I, et al. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. J Rheumatol 39:6 (2012), 1198–1206.
40. Smolen, JS, Landewe, R, Bijlsma, J, Burmester, G, Chatzidionysiou, K, Dougados, M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:6 (2017), 960–977.
41. Chaudhari, K, Rizvi, S, Syed, BA, Rheumatoid arthritis: current and future trends. Nat Rev Drug Discov 15:5 (2016), 305–306.
42. Hirten, RP, Iacucci, M, Shah, S, Ghosh, S, Colombel, JF, Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders. Clin Gastroenterol Hepatol 16:9 (2018), 1374–1384.
43. Inui, K, Koike, T, Combination therapy with biologic agents in rheumatic diseases: current and future prospects. Ther Adv Musculoskelet Dis 8:5 (2016), 192–202.
44. Bethge, J, Meffert, S, Ellrichmann, M, Conrad, C, Nikolaus, S, Schreiber, S, Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis. BMJ Open Gastroenterology, 4(1), 2017, e000127.
45. Di Paolo, J, Franci, C, Gentzler, T, Murray, B, Li, L, Targeting the BTK-JAK axis in preclinical models of rat collagen-induced arthritis with GS-4059 in combination with a JAK inhibitor. 2016 ACR/ARHP Annual Meeting, 2016.
46. Kaur, M, Singh, M, Silakari, O, Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: designing, synthesis and biological evaluation. Future Med Chem 9:11 (2017), 1193–1211.
47. Kelly, V, Genovese, M, Novel small molecule therapeutics in rheumatoid arthritis. Rheumatology (Oxford) 52:7 (2013), 1155–1162.
48. van der Maas, A, Kievit, W, van den Bemt, BJ, van den Hoogen, FH, van Riel, PL, den Broeder, AA, Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 71:11 (2012), 1849–1854.
49. Smolen, JS, Nash, P, Durez, P, Hall, S, Ilivanova, E, Irazoque-Palazuelos, F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 381:9870 (2013), 918–929.
50. Mena-Vazquez, N, Manrique-Arija, S, Yunquera-Romero, L, Urena-Garnica, I, Rojas-Gimenez, M, Domic, C, et al. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study. Rheumatol Int 37:10 (2017), 1709–1718.
51. Curtis, JR, Xie, F, Yun, H, Bernatsky, S, Winthrop, KL, Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 75:Suppl 2 (2016), 506.2–507.
52. Harigai, M., Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 58:Supplement_1 (2019), i34–i42.
53. Winthrop, KL, The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13:4 (2017), 234–243.
54. Winthrop, KL, Yamanaka, H, Valdez, H, Mortensen, E, Chew, R, Krishnaswami, S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 66:10 (2014), 2675–2684.
55. Souto, A, Salgado, E, Maneiro, JR, Mera, A, Carmona, L, Gomez-Reino, JJ, Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 67:1 (2015), 117–127.
56. Szekanecz, Z, Kerekes, G, Soltesz, P, Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 5:12 (2009), 677–684.
57. Choy, E, Ganeshalingam, K, Semb, AG, Szekanecz, Z, Nurmohamed, M, Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 53:12 (2014), 2143–2154.
58. Myasoedova, E, Crowson, CS, Kremers, HM, Roger, VL, Fitz-Gibbon, PD, Therneau, TM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70:3 (2011), 482–487.
59. Kerekes, G, Nurmohamed, MT, Gonzalez-Gay, MA, Seres, I, Paragh, G, Kardos, Z, et al. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol 10:11 (2014), 691–696.
60. Giles, J, Sattar, N, Gabriel, SE, Ridker, PM, Gay, S, Warne, C, et al. Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, noninferiority, phase 4 clinical trial [abstract]. Arthritis Rheumatol, 68(Suppl. 10), 2016.
61. Greenberg, JD, Kremer, JM, Curtis, JR, Hochberg, MC, Reed, G, Tsao, P, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 70:4 (2011), 576–582.
62. Dixon, WG, Symmons, DP, What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis 66:9 (2007), 1132–1136.
63. Roubille, C, Richer, V, Starnino, T, McCourt, C, McFarlane, A, Fleming, P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74:3 (2015), 480–489.
64. Ridker, PM, Everett, BM, Thuren, T, MacFadyen, JG, Chang, WH, Ballantyne, C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:12 (2017), 1119–1131.
65. Peters, MJ, Welsh, P, McInnes, IB, Wolbink, G, Dijkmans, BA, Sattar, N, et al. Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Ann Rheum Dis 69:7 (2010), 1281–1285.
66. Yokoe, I, Kobayashi, H, Kobayashi, Y, Giles, JT, Yoneyama, K, Kitamura, N, et al. Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms. Scand J Rheumatol 47:5 (2018), 364–370.
67. Pusztai, A, Végh, E, Váncsa, A, Bodnár, N, Szamosi, S, Nagy, G, et al. Effects of anti-TNF therapy on circulating oxLDL-beta2GPI levels in arthritis. Ann Rheum Dis, 74(Suppl. 2), 2015, 918.
68. Kerekes, G, Soltesz, P, Szucs, G, Szamosi, S, Der, H, Szabo, Z, et al. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr Med Assoc J 13:3 (2011), 147–152.
69. Lazzerini, PE, Acampa, M, Capecchi, PL, Fineschi, I, Selvi, E, Moscadelli, V, et al. Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation. Arthritis Care Res (Hoboken) 67:3 (2015), 332–339.
70. Lazzerini, PE, Laghi-Pasini, F, Boutjdir, M, Capecchi, PL, Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. Nat Rev Immunol 19:1 (2019), 63–64.
71. van den Oever, IA, Sattar, N, Nurmohamed, MT, Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Ann Rheum Dis 73:6 (2014), 954–957.
72. Ingegnoli, F, Fantini, F, Favalli, EG, Soldi, A, Griffini, S, Galbiati, V, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 31:2 (2008), 175–179.
73. McInnes, IB, Thompson, L, Giles, JT, Bathon, JM, Salmon, JE, Beaulieu, AD, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 74:4 (2015), 694–702.
74. Scott, IC, Hider, SL, Scott, DL, Thromboembolism with Janus Kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk?. Drug Saf 41:7 (2018), 645–653.
75. Smolen, JS, Genovese, MC, Takeuchi, T, Hyslop, DL, Macias, WL, Rooney, T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol 46:1 (2019), 7–18.
76. Harigai, M, Takeuchi, T, Smolen, JS, Winthrop, KL, Nishikawa, A, Rooney, TP, et al. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of phases 2 and 3 trials. Mod Rheumatol, 2019, 1–8.
77. Genovese, MC, Fleischmann, R, Combe, B, Hall, S, Rubbert-Roth, A, Zhang, Y, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 391:10139 (2018), 2513–2524.
78. Gotestam Skorpen, C, Hoeltzenbein, M, Tincani, A, Fischer-Betz, R, Elefant, E, Chambers, C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75:5 (2016), 795–810.
79. Atzeni, F, Talotta, R, Salaffi, F, Cassinotti, A, Varisco, V, Battellino, M, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 12:7 (2013), 703–708.
80. Yun, H, Xie, F, Beyl, RN, Chen, L, Lewis, JD, Saag, KG, et al. Risk of hypersensitivity to biologic agents among medicare patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 69:10 (2017), 1526–1534.
81. Curtis, JR, Hobar, C, Hansbrough, K, Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics. Curr Med Res Opin 27:1 (2011), 71–78.
82. Maneiro, JR, Salgado, E, Gomez-Reino, JJ, Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med 173:15 (2013), 1416–1428.
83. Deehan, M, Garcês, S, Kramer, D, Baker, MP, Rat, D, Roettger, Y, et al. Managing unwanted immunogenicity of biologicals. Autoimmun Rev 14:7 (2015), 569–574.
84. Pecoraro, V, De Santis, E, Melegari, A, Trenti, T, The impact of immunogenicity of TNFα inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis. Autoimmun Rev 16:6 (2017), 564–575.
85. Stewart, KD, Johnston, JA, Matza, LS, Curtis, SE, Havel, HA, Sweetana, SA, et al. Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence 10 (2016), 1385–1399.
86. Sarzi-Puttini, P, Ceribelli, A, Marotto, D, Batticciotto, A, Atzeni, F, Systemic rheumatic diseases: from biological agents to small molecules. Autoimmun Rev 18:6 (2019), 583–592.
87. Schwartz, DM, Kanno, Y, Villarino, A, Ward, M, Gadina, M, O'Shea, JJ, JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov, 17(1), 2017, 78.
88. Liongue, C, Ward, AC, Evolution of the JAK-STAT pathway. JAKSTAT, 2(1), 2013, e22756.
89. O'Shea, JJ, Holland, SM, Staudt, LM, JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368:2 (2013), 161–170.
90. O'Shea, JJ, Kontzias, A, Yamaoka, K, Tanaka, Y, Laurence, A, Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis, 72(Suppl. 2), 2013 ii111-5.
91. O'Shea, JJ, Laurence, A, McInnes, IB, Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol 9:3 (2013), 173–182.
92. Conigliaro, P, Triggianese, P, De Martino, E, Fonti, GL, Chimenti, MS, Sunzini, F, et al. Challenges in the treatment of rheumatoid arthritis. Autoimmun Rev 18:7 (2019), 706–713.
93. Hirahara, K, Schwartz, D, Gadina, M, Kanno, Y, O'Shea, JJ, Targeting cytokine signaling in autoimmunity: back to the future and beyond. Curr Opin Immunol 43 (2016), 89–97.
94. Ghoreschi, K, Jesson, MI, Li, X, Lee, JL, Ghosh, S, Alsup, JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186:7 (2011), 4234–4243.
95. O'Shea, JJ, Schwartz, DM, Villarino, AV, Gadina, M, McInnes, IB, Laurence, A, The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66 (2015), 311–328.
96. van der Heijde, D, Tanaka, Y, Fleischmann, R, Keystone, E, Kremer, J, Zerbini, C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65:3 (2013), 559–570.
97. Kremer, J, Li, ZG, Hall, S, Fleischmann, R, Genovese, M, Martin-Mola, E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159:4 (2013), 253–261.
98. Burmester, GR, Blanco, R, Charles-Schoeman, C, Wollenhaupt, J, Zerbini, C, Benda, B, et al. investigators OS. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:9865 (2013), 451–460.
99. Genovese, MC, Kremer, JM, Kartman, CE, Schlichting, DE, Xie, L, Carmack, T, et al. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis. Rheumatology (Oxford) 57:5 (2018), 900–908.
100. Burmester, GR, Kremer, JM, Van den Bosch, F, Kivitz, A, Bessette, L, Li, Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391:10139 (2018), 2503–2512.
101. Fleischmann, R, Mysler, E, Hall, S, Kivitz, AJ, Moots, RJ, Luo, Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 390:10093 (2017), 457–468.
102. Taylor, PC, Keystone, EC, van der Heijde, D, Weinblatt, ME, Del Carmen, ML, Reyes Gonzaga, J, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med 376:7 (2017), 652–662.
103. Fleischmann, R, Pangan, A, Mysler, E, et al. A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate. Arthritis Rheumatol, 70(Suppl. 10), 2018.
104. Nam, JL, Takase-Minegishi, K, Ramiro, S, Chatzidionysiou, K, Smolen, JS, van der Heijde, D, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 76:6 (2017), 1113–1136.
105. Boone, NW, Sepriano, A, van der Kuy, PH, Janknegt, R, Peeters, R, Landewé, RBM, Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time. RMD Open, 5(1), 2019, e000836.
106. Favalli, EG, Pregnolato, F, Biggioggero, M, Becciolini, A, Penatti, AE, Marchesoni, A, et al. Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care Res (Hoboken) 68:4 (2016), 432–439.
107. Emery, P, Sebba, A, Huizinga, TW, Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 72:12 (2013), 1897–1904.
108. Favalli, EG, Becciolini, A, Biggioggero, M, Bertoldi, I, Crotti, C, Raimondo, MG, et al. The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. Drug Des Devel Ther 12 (2018), 1421–1429.
109. Gabay, C, Emery, P, van Vollenhoven, R, Dikranian, A, Alten, R, Pavelka, K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381:9877 (2013), 1541–1550.
110. Burmester, GR, Lin, Y, Patel, R, van Adelsberg, J, Mangan, EK, Graham, NM, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 76:5 (2017), 840–847.
111. Dougados, M, Kissel, K, Conaghan, PG, Mola, EM, Schett, G, Gerli, R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 73:5 (2014), 803–809.
112. Fleischmann, R, Schiff, M, van der Heijde, D, Ramos-Remus, C, Spindler, A, Stanislav, M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:3 (2017), 506–517.
113. Lee, EB, Fleischmann, R, Hall, S, Wilkinson, B, Bradley, JD, Gruben, D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:25 (2014), 2377–2386.
114. Strand, V, Wright, GC, Bergman, MJ, Tambiah, J, Taylor, PC, Patient expectations and perceptions of goal-setting strategies for disease management in rheumatoid arthritis. J Rheumatol 42:11 (2015), 2046–2054.
115. Her, M, Kavanaugh, A, Patient-reported outcomes in rheumatoid arthritis. Curr Opin Rheumatol 24:3 (2012), 327–334.
116. Keystone, EC, Taylor, PC, Tanaka, Y, Gaich, C, DeLozier, AM, Dudek, A, et al. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis 76:11 (2017), 1853–1861.
117. Fautrel, B, Zhu, B, Taylor, P, van de Laar, M, Emery, P, de Leonardis, F, et al. Comparative effectiveness in pain and HAQ-DI improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naïve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC) [abstract]. Arthritis Rheumatol, 70(Suppl. 10), 2018.
118. Crotti, C, Agape, E, Becciolini, A, Biggioggero, M, Favalli, EG, Targeting granulocyte-monocyte colony-stimulating factor signaling in rheumatoid arthritis: future prospects. Drugs 79:16 (2019), 1741–1755.
119. Banerjee, S, Biehl, A, Gadina, M, Hasni, S, Schwartz, DM, JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 77:5 (2017), 521–546.
120. Cohen, SB, Tanaka, Y, Mariette, X, Curtis, JR, Lee, EB, Nash, P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76:7 (2017), 1253–1262.
121. Strand, V, Ahadieh, S, French, J, Geier, J, Krishnaswami, S, Menon, S, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther, 17, 2015, 362.
122. Cantini, F, Niccoli, L, Capone, A, Petrone, L, Goletti, D, Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf 18:5 (2019), 415–425.
123. Schieir, O, Tosevski, C, Glazier, RH, Hogg-Johnson, S, Badley, EM, Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann Rheum Dis 76:8 (2017), 1396–1404.
124. Holmqvist, ME, Neovius, M, Eriksson, J, Mantel, Ä, Wållberg-Jonsson, S, Jacobsson, LT, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 308:13 (2012), 1350–1356.
125. Corrales, A, González-Juanatey, C, Peiró, ME, Blanco, R, Llorca, J, González-Gay, MA, Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 73:4 (2014), 722–727.
126. López-Mejías, R, Castañeda, S, González-Juanatey, C, Corrales, A, Ferraz-Amaro, I, Genre, F, et al. Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers. Autoimmun Rev 15:11 (2016), 1013–1030.
127. Blum, A, Adawi, M, Rheumatoid arthritis (RA) and cardiovascular disease. Autoimmun Rev 18:7 (2019), 679–690.
128. Taylor, PC, Weinblatt, ME, Burmester, GR, Rooney, TP, Witt, S, Walls, CD, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol 71:7 (2019), 1042–1055.
129. Desai, RJ, Pawar, A, Weinblatt, ME, Kim, SC, Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational Cohort study. Arthritis Rheumatol 71:6 (2019), 892–900.